Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF

Journal of Medical Virology

Volumn 86, Issue 9, 2014, Pages 1473-1481

  Liu, Yang ^a   Fung, Scott ^b   Gane, Edward J ^c   Dinh, Phillip ^a   Flaherty, John F ^a   Svarovskaia, Evguenia S ^a   Miller, Michael D ^a   Kitrinos, Kathryn M ^a  

^a GILEAD SCIENCES   (United States)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c New Zealand Liver Transplant Unit   (New Zealand)

Author keywords

Allele specific PCR (AS PCR); Chronic hepatitis B; LAM R rtM204V I; Tenofovir disoproxil fumarate (TDF); Viral load decay

Indexed keywords

EMTRICITABINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE;

ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS DETECTION; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; GENETIC ASSOCIATION; GENETICS; HEPATITIS B, CHRONIC; KINETICS; MISSENSE MUTATION; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DNA, VIRAL; DRUG THERAPY, COMBINATION; GENETIC ASSOCIATION STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KINETICS; MUTATION, MISSENSE; ORGANOPHOSPHONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84903961484     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23982     Document Type: Article

References (24)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters K-A, Tyrrell DL, Brown N, Condreay LD, Lamivudine Clinical Investigation Group. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. 2013. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect 67:322-328.
3. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. 2009. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 50:42-48.
4. European Association for the Study of the Liver (EASL). 2012. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection [published version]. J Hepatol 57:167-185.
5. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison J, Husa P, Gane E. 2014. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146:980-988.
6. Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, Miller MD, Svarovskaia ES. 2011. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25:325-333.
7. Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M. 2007. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 14:835-840.
8. Kuo A, Dienstag JL, Chung RT. 2004. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2:266-272.
9. Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F. 2013. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology 58:912-922.
10. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. 2004. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9:353-363.
11. Lai C-L, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687-696.
12. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. 2005. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42:1414-1419.
13. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451.
14. Liaw YF. 2009. Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia. J Hepatol 51:403-410.
15. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano J, Suh DJ, Omata M. 2012. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int 6:531-561.
16. Lok AS, McMahon BJ. 2009. Chronic Hepatitis B: Update 2009. Hepatology 50:1-36.
17. Lok ASF, Lai C-L, Leung N, Yao G-B, Cui Z-Y, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
18. Moser MJ, Ruckstuhl M, Larsen CA, Swearingen AJ, Kozlowski M, Bassit L, Sharma PL, Schinazi RF, Prudent JR. 2005. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 49:3334-3340.
19. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. 2011. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53:763-773.
20. Svaroskaia E, Curtis M, Zhu Y, Borroto, -E.K., Miller M, Berg T, Lavocat F, Zoulim F, Kitrinos K. 2013. Hepatitis B virus wild-type and rtN236T populations show similar early DNA decline in adefovir refractory patients on a tenofovir-based regimen. J Viral Hepat 20:131-140.
21. Svarovskaia ES, Moser MJ, Bae AS, Prudent JR, Miller MD, Borroto-Esoda K. 2006. MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol 44:4237-4241.
22. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:1503-1514.
23. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80.
24. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV. 2005. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10:625-633.